ABA Chemicals (SHE:300261) plans to invest in Gansu Haotian Technology by acquiring existing shares and possibly subscribing to newly registered capital, according to a Monday filing with the Shenzhen Stock Exchange.
The move aims to enhance ABA Chemicals's pharmaceutical business by leveraging Haotian's CDMO and CRO expertise.
While discussions are ongoing, no formal agreement has been signed, and the investment structure is yet to be finalized. Further disclosures will be made as the deal progresses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.